Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS, AND METHODS

Last updated:

Abstract:

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

Status:
Application
Type:

Utility

Filling date:

10 Apr 2020

Issue date:

14 Jul 2022